- Home
- ERAS vs KIO Comparison
ERAS vs KIO Comparison
Compare ERAS & KIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- KIO
- Stock Information
- Founded
- ERAS 2018
- KIO 2011
- Country
- ERAS United States
- KIO United States
- Employees
- ERAS N/A
- KIO 2400
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- KIO Investment Managers
- Sector
- ERAS Health Care
- KIO Finance
- Exchange
- ERAS Nasdaq
- KIO Nasdaq
- Market Cap
- ERAS 439.7M
- KIO 522.7M
- IPO Year
- ERAS 2021
- KIO N/A
- Fundamental
- Price
- ERAS $2.44
- KIO $12.08
- Analyst Decision
- ERAS Buy
- KIO
- Analyst Count
- ERAS 6
- KIO 0
- Target Price
- ERAS $3.67
- KIO N/A
- AVG Volume (30 Days)
- ERAS 2.1M
- KIO 136.5K
- Earning Date
- ERAS 11-07-2025
- KIO 01-01-0001
- Dividend Yield
- ERAS N/A
- KIO 10.82%
- EPS Growth
- ERAS N/A
- KIO N/A
- EPS
- ERAS N/A
- KIO N/A
- Revenue
- ERAS N/A
- KIO N/A
- Revenue This Year
- ERAS N/A
- KIO N/A
- Revenue Next Year
- ERAS N/A
- KIO N/A
- P/E Ratio
- ERAS N/A
- KIO N/A
- Revenue Growth
- ERAS N/A
- KIO N/A
- 52 Week Low
- ERAS $1.01
- KIO $10.52
- 52 Week High
- ERAS $3.31
- KIO $13.59
- Technical
- Relative Strength Index (RSI)
- ERAS 59.41
- KIO 47.63
- Support Level
- ERAS $2.18
- KIO $11.57
- Resistance Level
- ERAS $2.65
- KIO $12.50
- Average True Range (ATR)
- ERAS 0.15
- KIO 0.15
- MACD
- ERAS -0.03
- KIO 0.02
- Stochastic Oscillator
- ERAS 55.79
- KIO 54.84
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.